// App-Quantinova.ai

5581 : Pembrolizumab in advanced endometrial cancer: preliminary results from the phase 1b KEYNOTE-028 study.

Researchers

Presenter

  • Patrick Alexander Ott

Principal Investigators

  • Yung-Jue Bang

  • Dominique Berton-Rigaud

  • Elena Elez

  • Michael J. Pishvaian

  • Hope S. Rugo

  • Igor Puzanov

  • Mark Aloysuis Morgan

  • Janice M. Mehnert

  • Kyaw Lwin Aung

  • Marion Carrigan

  • Sanatan Saraf

  • Mei Chen

  • Jean-Charles Soria

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Centre Rene Gauducheau, Saint-Herblain, France

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • University of California, San Francisco, San Francisco, CA

  • Vanderbilt University Medical Center, Nashville, TN

  • University of Pennsylvania, Philadelphia, PA

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Merck & Co., Inc., Kenilworth, NJ

  • Gustave Roussy Cancer Campus, Villejuif, France

Locations

  • United States

  • Spain

  • France

  • Canada

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Endometrial Cancer

  • Solid malignancies

  • Sarcoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02054806

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved